Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

NCT07494045 | Not Yet Recruiting Phase 2 FDA Drug

• 1 other identifier: CTAP101-CL-2015
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 5

Brief Summary

The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are:

1. 1.To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules
2. 2.To investigate the safety and tolerability of CTAP101 Capsules

Conditions

CKD Stage 3; CKD Stage 4; Secondary Hyperparathyroidism; VDI

Outcome Measures

Primary Outcomes (4)

• Apparent clearance (CL/F)

  To determine the CL/F of CTAP101 Capsules during and after repeated dosing

  Up to 14 weeks

• Volume of distribution (Vd/F)

  To determine the Vd/F of CTAP101 Capsules during and after repeated dosing

  Up to 14 weeks

• Terminal elimination half-life (t1/2)

  To determine the t1/2 of CTAP101 Capsules during and after repeated dosing

  Up to 14 weeks

• Incidence of treatment emergent adverse events (TEAE)

  TEAEs will be graded as mild, moderate, severe.

  Up to 14 weeks

Study Arms (2)

Cohort 1 - Group A

EXPERIMENTAL

30 mcg CTAP101 Capsules

Drug: CTAP101

Cohort 1 - Group B

EXPERIMENTAL

30 mcg or 60 mcg CTAP101 Capsules

Drug: CTAP101

Interventions

CTAP101 DRUG

Capsules

Cohort 1 - Group A; Cohort 1 - Group B

Eligibility Criteria

• Age: 1 Month - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Each participant must meet the following criteria to be enrolled in Cohort 1 of this study:
• Be 8 to \<18 years of age with a body weight of ≥40 kg.
• Be diagnosed with stage 3 or 4 CKD at least six months prior to the screening visit (Visit 1) and have an eGFR of ≥15 to \<60 mL/min/1.73m2 at screening.
• Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation.
• Exhibit during the initial or, if necessary, a screening visit after washout:
• Plasma iPTH \>85 pg/mL;
• Serum Ca \<9.8 mg/dL;
• Serum P ≤5.5 mg/dL; and
• Serum 25D \<30 ng/mL.
• If taking calcitriol or other 1α-hydroxylated vitamin D therapy, be willing to forgo treatment with these agents for the duration of the study and complete a 2-week washout period prior to commencing treatment in the study.
• If receiving ≤2,000 IU/day or 50,000 IU/month (1,250 mcg) vitamin D supplementation (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.
• If taking \>2,000 IU/day of vitamin D supplementation, must discontinue or decrease the dose to ≤2,000 IU/day, maintain that dose for the duration of the study and complete a 2-week washout period prior to commencing treatment in the study.
• If taking \>1000 mg/day of elemental Ca through Ca-based phosphate binder or antacid therapy, must discontinue or decrease the dose to ≤ 1000 mg/day, maintain that dose for the duration of the study, and complete a 2-week washout period prior to commencing treatment in the study.
• If taking any bone metabolism therapy that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.
• Willing and able to comply with study procedures and instructions and commit to all study visits for the duration of the study.

You may not qualify if:

• Participants who meet any of the following criteria will be excluded from the study:
• Kidney transplant within the 26 weeks preceding screening or kidney transplant rejection within the 26 weeks preceding screening.
• No history of parathyroidectomy or planned parathyroidectomy.
• History (prior three months) of serum Ca ≥9.8 mg/dL.
• Use of calcimimetic or calcifediol therapy within three months prior to consent.
• Use of bisphosphonate or denosumab therapy within six months prior to consent.
• Known or suspected hypersensitivity to any of the constituents in CTAP101 Capsules.
• Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or abnormal ECG or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.
• History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or FU schedule unlikely.
• Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening that in the opinion of the investigator and/or sponsor would interfere with the safety, assessments, and results of this study.

Sponsors & Collaborators

• OPKO Health, Inc.: lead

Study Sites (5)

OPKO Site

Kansas City, Missouri, 64108, United States

Location

OPKO Site

Columbus, Ohio, 43205, United States

Location

OPKO Site

Philadelphia, Pennsylvania, 19104, United States

Location

OPKO Site

Greenville, South Carolina, 29615, United States

Location

OPKO Site

Madison, Wisconsin, 53562, United States

Location

MeSH Terms

Conditions

Hyperparathyroidism, Secondary

Condition Hierarchy (Ancestors)

Hyperparathyroidism; Parathyroid Diseases; Endocrine System Diseases

Central Study Contacts

OPKO Health

CONTACT

305-575-4100; contact@opko.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 20, 2026
• First Posted: March 27, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): October 1, 2027
• Study Completion (Estimated): August 1, 2028
• Last Updated: March 30, 2026

Record last verified: 2026-03

Locations

US (5)